Table 1.

Patient characteristics and their impact on the detection of H-Y antigen–specific antibodies at 3 months posttransplant

	N	Any HY-Ab seropositivity 3 mo post-HCT, n (%)	HY-Ab seronegativity 3 mo post-HCT, n (%)	P
Total cohort	136	78 (57%)	58 (42%)
Patient age, y
<50	58	31 (40%)	27 (47%)	.49
≥50	78	47 (60%)	31 (53%)
Donor age, y
<50	92	50 (64%)	42 (72%)	.46
≥50	43	27 (35%)	16 (28%)
Missing	1
Disease
AML	38	23 (29%)	15 (26%)	.79
ALL	26	16 (21%)	10 (17%)
MDS, MPN	19	12 (15%)	7 (12%)
Lymphoma	48	25 (32%)	23 (40%)
Others	5	2 (3%)	3 (5%)
Disease risk
Standard	105	57 (73%)	48 (83%)	.22
High	31	21 (27%)	10 (17%)
CMV seropositivity
D+R+	52	27 (35%)	25 (43%)	.15
D+R−	24	18 (23%)	8 (14%)
D−R+	26	17 (22%)	7 (12%)
D−R−	34	16 (21%)	18 (31%)
Donor type
MRD	81	48 (62%)	33 (57%)	.88
MUD	33	19 (24%)	14 (24%)
MMRD	4	2 (3%)	2 (3%)
MMUD	18	9 (12%)	9 (16%)
Cell source
Bone marrow	8	4 (5%)	4 (7%)	.72
Peripheral blood	128	74 (95%)	54 (93%)
GVHD prophylaxis
CsA-based	82	48 (62%)	34 (59%)	.87
Tac-based	48	27 (35%)	21 (36%)
Others	6	3 (4%)	3 (5%)
Conditioning
MAC	64	35 (45%)	29 (50%)	.60
RIC	72	43 (55%)	29 (50%)
With ATG	70	43 (55%)	27 (47%)	.39
Without ATG	66	35 (45%)	31 (53%)
aGVHD
Grade 0-1	105	66 (85%)	39 (67%)	.044
Grade 2	23	8 (10%)	15 (26%)
Grade 3-4	8	4 (5%)	4 (7%)

ALL, acute lymphoblastic leukemia; AML, acute myelogenous leukemia; ATG, anti-thymocyte globulin; CMV, cytomegalovirus; CsA, cyclosporine; D, donor CMV seropositivity; MAC, myeloablative conditioning; MDS, myelodysplastic syndrome; MMRD, HLA-mismatched related donor; MMUD, HLA-mismatched unrelated donor; MPN, myeloproliferative neoplasm; R, recipient CMV seropositivity; MRD, HLA-matched related donor; MUD, HLA-matched unrelated donor; RIC, reduced intensity conditioning; Tac, tacrolimus.